When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...
DENVER -- A daily, single-tablet combination of bictegravir and lenacapavir (Yeztugo) was noninferior to complex multi-tablet ...
Matthew Galsky, M.D., FASCO, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, will present the late-breaking abstract in a rapid oral presentation titled “Updated clinical results ...
In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...
This transition is explored in “Embodied Artificial Intelligence in Healthcare: A Systematic Review of Robotic Perception, ...
Sogroya® (somapacitan-beco) is a once-weekly treatment option, offering an alternative to once-daily therapy, which may help ...
Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...
3hon MSN
Transcript: Rare Diseases
Transcript: Rare Diseases ...
Divergence in the post-progression interval suggests disparities may concentrate in subsequent-line therapy, surveillance, supportive care, or access to timely interventions outside trial ...
In the 30 years since Pokémon debuted in Japan with the 1996 release of Pokémon Red and Pokémon Green for Nintendo Game Boy, ...
The University of Warwick, which is setting up the Registry, plans to collect data for analysis from 500 AML patients at sites in 30 large metropolitan NHS hospitals across the UK by the end of this ...
The preclinical pharmacokinetic (PK) and pharmacodynamic (PD) studies, conducted in cynomolgus monkeys following subcutaneous and intravenous administration, demonstrated rapid downregulation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results